Merck KGaA, Darmstadt, Germany, Invests € 35 Million in its Italian Biotech Manufacturing Site of Bari
Download PDF Read more
Category: Bio/Pharma/CRO
HORIZON Particle Analysis Launches in Europe at MIBio 2017
The HORIZON subvisible particle analysis system The HORIZON subvisible particle analysis system PHILADELPHIA, Oct. 2, 2017 /PRNewswire/ — Halo Labs announces the European launch of their new low volume, high throughput biopharmaceutical particle analysis system called the HORIZON at MIBio 2017 in Cambridge, U.K on October 4th. The new system analyzes subvisible and visible particulate matter in biopharmaceutical samples... Read more
MilliporeSigma Provides Update on EU’s Horizon 2020 Program to Improve Biopharmaceutical Downstream Processing
Download PDF Read more
Shimadzu’s New Nexera FV Ultra High Performance Liquid Chromatograph Dramatically Reduces the Time Spent Conducting Dissolution Tests for the Development and Quality Control of Pharmaceuticals
Evaluation of the dissolution of drug products is important in the development and quality control of pharmaceuticals. Especially for generic pharmaceuticals, a dissolution test must be performed to validate their bioequivalence and whether it has been changed by the content and dosage form. Ultraviolet spectrophotometers are mainly used to measure the dissolution amount. However, a... Read more
First patient enrolled into phase I clinical trial of Oncolytic Virus HF10 against pancreatic cancer in Japan
First patient enrolled into phase I clinical trial of Oncolytic Virus HF10 against pancreatic cancer in Japan Kusatsu/Shiga, Japan — September 27, 2017 — Takara Bio Inc. (Takara Bio), today announced that the first patient with pancreatic cancer has been enrolled into Oncolytic Virus HF10(TBI-1401) phase I clinical trial in Japan on September 26, 2017. This... Read more
Agilent Technologies Receives Expanded FDA Approval for the Use of Dako PD-L1 IHC 22C3 pharmDx Companion Diagnostic in Gastric or Gastroesophageal Junction (GEJ) Cancer
Patients with gastric or GEJ adenocarcinoma whose tumors express PD-L1 can now be identified for potential treatment with KEYTRUDA® (pembrolizumab) using PD-L1 IHC 22C3 pharmDx SANTA CLARA, Calif., September 22, 2017 Agilent Technologies Inc. (NYSE: A) today announced its Dako PD-L1 IHC 22C3 pharmDx assay has an expanded label approved by U.S. Food and Drug... Read more
Roche receives EU approval of TECENTRIQ® (atezolizumab) in a specific type of metastatic lung cancer and two types of metastatic bladder cancer
Basel, 22 September 2017 Roche receives EU approval of TECENTRIQ® (atezolizumab) in a specific type of metastatic lung cancer and two types of metastatic bladder cancer TECENTRIQ provides a new treatment option for people with previously treated locally advanced or metastatic non-small cell cancer (NSCLC) TECENTRIQ is a new treatment option for people with metastatic... Read more
Roche receives EU approval of Gazyvaro for people with previously untreated advanced follicular lymphoma
Basel, 22 September 2017 Roche receives EU approval of Gazyvaro for people with previously untreated advanced follicular lymphoma Approval is based on phase III GALLIUM study results, which showed superior progression-free survival for Gazyva/Gazyvaro compared to MabThera/Rituxan Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved Gazyvaro® (obinutuzumab) in combination... Read more
European Commission Approves Bavencio (Avelumab) for Metastatic Merkel Cell Carcinoma
Download PDF Read more
Phase III data showed that Venclexta/Venclyxto plus MabThera/Rituxan helped people with previously treated chronic lymphocytic leukaemia live longer without their disease worsening compared to bendamustine plus MabThera/Rituxan
Basel, 18 September 2017 Phase III data showed that Venclexta/Venclyxto plus MabThera/Rituxan helped people with previously treated chronic lymphocytic leukaemia live longer without their disease worsening compared to bendamustine plus MabThera/Rituxan Data from pivotal phase III study will be submitted to health authorities and presented at an upcoming medical meeting Roche (SIX: RO, ROG; OTCQX:... Read more